Week in Review: D3 Bio Raises $62 Million for Trials of KRAS G12C Inhibitor

Deals and Financings

• D3 Bio of Shanghai closed a $62 million Series A+ financing round to conduct global trials of a KRAS G12C inhibitor and ramp up development of its preclinical assets;
• Sino Biopharm formed a strategic partnership with Germany’s Boehringer Ingelheim to develop Boehringer 's innovative oncology pipeline in mainland China;
• Suzhou Transcenta partnered with California’s Agilent Technologies to develop a companion diagnostic for Osemitamab, a Claudin18.2 mAb;

Trials and Approvals

• Shanghai Junshi Biosciences was approved to market a combination of toripalimab and axitinib as a first-line treatment for advanced renal cell;
• Hangzhou Jiuyuan Gene Engineering filed for approval of their biosimilar to Novo Nordisk’s Ozempic (semaglutide), a weight loss drug;
• Beijing’s YS Biopharma reported positive results from the ongoing Phase III clinical trial of its next-gen PIKA Rabies Vaccine;
• Shenzhen Kexing Biopharm started a Phase III clinical trial of an inhaled Interferon aIb therapy for respiratory syncytial virus infections in children;
• Shanghai Abbisko Therapeutics has completed patient enrollment for a global Phase III trial of pimicotinib in patients with tenosynovial giant cell tumor;
• Sichuan Kelun-Biotech and Merck reported early Phase I/II data showing their TROP2-directed ADC produced a promising disease control rate;
• Suzhou VesiCURE Therapeutics reports its mesenchymal stem cell-derived extracellular vesicles showed efficacy in a mouse model of ulcerative colitis.
  
  Share this with colleagues: